TCR-engineered cell-based therapies directed against MAGE proteins, NY-ESO-1, and other CTA, as well as anti-tumor vaccines targeting these antigens, have been evaluated as clinical targets in a number of studies [8, 51, 52]. Here, CTAG1A is linked to neoplasm.